• First patient safely dosed in Phase 1 clinical trial of RC220 in advanced solid tumour patients
• Trial will determine safety, tolerability and pharmacokinetic data of RC220, plus the maximum tolerated combined dose of RC220 with doxorubicin
• Up to another 32 patients to be recruited across multiple sites in Australia, Hong Kong and South Korea in first stage of the trial

Race Oncology Ltd is pleased to announce the successful and safe dosing of the first patient with RC220 in its Phase 1 clinical trial in advanced solid tumours. The patient was treated by Prof Paul de Souza and his team at the study's lead trial site, Southside Cancer Care Centre, Miranda, NSW. No phlebitis (vein inflammation) or any other adverse events were reported. Race's Phase 1 solid tumour clinical trial is open-label and will be conducted across multiple sites in Australia, Hong Kong and South Korea. Stage 1 of the trial will use ascending doses of RC220 to determine the safety, tolerability, pharmacokinetics and maximum tolerated combined dose (MTCD) of RC220 in combination with doxorubicin in up to 33 patients. Effects on a range of clinical biomarkers including m6A RNA will also be examined. After interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients in Stage 2 for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design, enabling greater trial flexibility and speed than previous approaches. As the trial is open-label in nature, patient outcomes will be obtained soon after patients are treated. Race intends to announce progress updates on the trial on a regular basis, but not at the individual patient level.

Race Oncology is not providing any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics in this announcement.

Race Oncology is not providing any forward-looking outlook in this announcement.